Pierian Biosciences Inc in Nashville, Tennessee have developed two cancer treatment selective platforms.

ChemoIntel: In vitro bioassay for ranking chemotherapy in order of effectiveness for any individual patient. The ChemoIntel test is based on multiple parameters to eliminate outlier readings. The method has proved reliable as a personalised alternative to general standard of care prescribing.

ImmunoIntel: Diagnostic method for ranking immunotherapy treatments for cancer in order of effectiveness for any individual patient. Biopsy cells are

tested in reproduced micro environment conditions. The two assays, together, transform the process of choosing the right treatment for the right patient. It is believed insurers and health services will require this before paying for

treatment. It avoids treating patients with potentially harmful drugs and procedures that may not produce the desired response.

A unique wealth of valuable data has been built up over several years of development. This has considerable and enduring value in a field that is  chronically short of clinical data. Two new laboratories have now been opened in Liverpool allowing access to human tissue samples from across Europe. 

Pierian has now signed a Service Level Agreement with a major UK Cancer Hospital and moves forward with its Cancer Assay Algorithm Development Study prior to FDA trials. 

Targeted returns of x8 

Exit horizon is 12 – 18 months.